These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35016192)

  • 1. Preliminary Clinical Validation of a Filtration-Based CTC Assay for Tumor Burden and HER2 Status Monitoring in Metastatic Breast Cancer.
    Wang X; Han C; Liang J; Yi J; Pan Z; Wang Y
    Oncol Res Treat; 2022; 45(4):157-165. PubMed ID: 35016192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
    Müller V; Banys-Paluchowski M; Friedl TWP; Fasching PA; Schneeweiss A; Hartkopf A; Wallwiener D; Rack B; Meier-Stiegen F; Huober J; Rübner M; Hoffmann O; Müller L; Janni W; Wimberger P; Jäger B; Pantel K; Riethdorf S; Harbeck N; Fehm T;
    ESMO Open; 2021 Dec; 6(6):100299. PubMed ID: 34839105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-targeted therapy influences CTC status in metastatic breast cancer.
    Deutsch TM; Riethdorf S; Fremd C; Feisst M; Nees J; Fischer C; Hartkopf AD; Pantel K; Trumpp A; Schütz F; Schneeweiss A; Wallwiener M
    Breast Cancer Res Treat; 2020 Jul; 182(1):127-136. PubMed ID: 32436146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
    Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
    Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
    Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer.
    Chen W; Zhang J; Huang L; Chen L; Zhou Y; Tang D; Xie Y; Wang H; Huang C
    Clin Breast Cancer; 2019 Feb; 19(1):e239-e246. PubMed ID: 30472074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer.
    Huai J; Cao M; Jiang Y; Yang X; Zhu Y; Si Y; Xu M; Shen C; Han T; Lian X
    Biomed Res Int; 2021; 2021():6388492. PubMed ID: 34901275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
    Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
    Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
    Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.
    Malani R; Fleisher M; Kumthekar P; Lin X; Omuro A; Groves MD; Lin NU; Melisko M; Lassman AB; Jeyapalan S; Seidman A; Skakodub A; Boire A; DeAngelis LM; Rosenblum M; Raizer J; Pentsova E
    J Neurooncol; 2020 Jul; 148(3):599-606. PubMed ID: 32506369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
    Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
    Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
    Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM
    Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
    Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY
    Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.